Imperial Innovations invests across the golden triangle formed between London, Cambridge and Oxford. This area is home to many groundbreaking technology companies through its proximity to some of the world's leading universities.
Innovations has proprietary access to intellectual property arising from research undertaken at Imperial College London. Many of our investments originate from the College, with which we have a deep and developed relationship.
Following our fundraising in January 2011, Innovations began a collaboration with UCLB, the spinout equity management organisation for University College London. A number of investments have resulted to date, including Autifony, which is developing novel therapeutics for tinnitus, hearing loss, and diseases of the central nervous system, and ASIO, a software developer focused on innovative data transfer methods.
Innovations has a productive collaboration in place with Cambridge Enterprise, the spinout equity management organisation for the University of Cambridge. Since January 2011, we have made five investments in Cambridge companies, including MISSION Therapeutics, a developer of cancer therapeutics based on new understanding of the DNA damage response; Featurespace, a software company developing predictive analytics for fraud prevention and marketing purposes; and Acunu, a software firm providing big data applications at accesible prices.
Innovations has access to later-stage Oxford companies through its collaboration with Oxford Spinout Equity Management, which provides spinout equity management services to Oxford University. Since January 2011, Innovations has made two investments in Oxford companies, including leading a significant Series G funding round for Oxford Immunotec, a diagnostics platform company focused on developing a rapid assay for latent tuberculosis infection.